| 04/01/2025 08:30 |
Shionogi Initiates New Drug Application Submission for Ensitrelvir for Post-Exposure Prophylaxis with the U.S. Food and Drug Administration |
| 03/27/2025 12:30 |
Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Post-Exposure Prophylaxis of COVID-19. |
| 03/24/2025 18:00 |
Notice of Transition to Company with Audit and Supervisory Committee and the Candidates for Directors After the Transition |
| 03/13/2025 11:30 |
Late-Breaking at CROI 2025: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylax |
| 01/31/2025 15:30 |
Financial Results for the 3rd Quarter of FY2024 Supplement |
| 01/31/2025 15:30 |
Consolidated Finacial Results for the Third Quarter of Fiscal Year 2024 (IFRS) |
| 01/31/2025 15:30 |
3rd Quarter of Fiscal 2024 Finacial Results |
| 01/30/2025 15:30 |
Shionogi Announces Positive Results from Phase 2 Trial of Respiratory Syncytial Virus Oral Antiviral Candidate S-337395 |
| 01/22/2025 11:30 |
Acceptance of a New Drug Application for the COVID-19 Treatment, Ensitrelvir Fumaric Acid, in Taiwan and Conclusion of Government Stockpiling Contract |
| 01/17/2025 08:59 |
Shionogi Receives Award Through BARDA's RRPV to Advance Long-Acting Formulation of S-892216 |
| 12/23/2024 15:30 |
Notice Regarding the Dissolution of Joint Ventures and Share Transfer Agreement with Ping An Insurance (Group) Company of China, Ltd. |
| 10/30/2024 12:00 |
Corporate Governance Report |
| 10/29/2024 17:00 |
Notice Regarding Actions to Achieve Management Conscious of Capital Costs and Stock Prices |
| 10/29/2024 15:00 |
Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19 |
| 10/28/2024 13:00 |
Notice of Revisions to Earnings Forecasts for the Fiscal Year Ending March 31, 2025 |
| 10/28/2024 13:00 |
1st Half (Interim period) of Fiscal 2024 Financial Results |
| 10/28/2024 13:00 |
Financial Results for the Second Quarter of Fiscal Year 2024 |
| 10/28/2024 13:00 |
Consolidated Finacial Results for the Second Quarter of Fiscal Year 2024 (IFRS) |
| 09/27/2024 11:30 |
Shionogi Submits New Drug Application in Japan for Zuranolone as a Treatment for Major Depressive Disorder |
| 08/30/2024 14:00 |
Notice Regarding Stock Split, Partial Amendment to Articles of Incorporation and Revision of Dividend Forecast |
| 08/05/2024 15:00 |
New Drug Application of Novel Siderophore Cephalosporin Antibiotics, Cefiderocol, Accepted in China |
| 07/29/2024 15:00 |
Consolidated Financial Results for the First Quarter of Fiscal Year 2024 (IFRS) |
| 07/29/2024 15:00 |
Supplemental material for financial results for the 1st quarter of fiscal year 2024 |
| 07/29/2024 15:00 |
1st Quarter of Fiscal 2024 Financial Results |
| 07/19/2024 15:00 |
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 07/01/2024 13:00 |
Corporate Governance Report |
| 06/24/2024 16:00 |
COVGOZE (Monovalent: Original Strain), Recombinant Protein COVID-19 Vaccine, Approved for Manufacturing and Marketing as Initial Immunization in Japan |
| 06/20/2024 17:00 |
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 06/06/2024 17:00 |
SHIONOGI R&D Day 2024 |
| 06/06/2024 17:00 |
SHIONOGI R&D Day 2024 |
| 05/31/2024 15:00 |
Position and Policy Regarding Reduction of the Investment Unit |
| 05/22/2024 08:00 |
Notice of Convocation of Annual General Meeting and Meeting Materials 2024 |
| 05/13/2024 15:00 |
Shionogi Provides Updates from SCORPIO-HR, a Global Phase 3 Study of Ensitrelvir for Non-Hospitalized Participants with COVID-19 |
| 05/13/2024 15:00 |
FY2023 Finacial Results |
| 05/13/2024 13:00 |
Financial results for the year ended March 31, 2024 |
| 05/13/2024 13:00 |
Consolidaterd Financial Resauts for Fiscal Year 2023 (IFRS) |
| 05/10/2024 15:00 |
Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease |
| 04/25/2024 15:00 |
Notice of Revisions to Dividend Forecasts (Dividend Increase) |
| 04/23/2024 17:00 |
Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents |
| 04/18/2024 11:30 |
Notice Regarding Completion of Cancellation of Treasury Shares |
